COVIDORNASE: Efficacy and Safety of Dornase Alfa Aerosol in ARDS Secondary to SARS-CoV-2 Coronavirus Respiratory Infection

77 patient dornase alfa late treatment RCT with results not reported over 4 years after completion.

4 dornase alfa RCTs have results missing long after expected1-4
The trials report a total of 297 patients, with 2 trials having actual enrollment of 177, and the remainder estimated.

Important missing comments or errors? Let us know.

1. Fowler et al., Pulmozyme to Improve COVID-19 ARDS Outcomes, NCT04402944, clinicaltrials.gov/study/NCT04402944clinicaltrials.gov.

2. Grégoire et al., Efficacy and Safety of Dornase Alfa Aerosol in ARDS Secondary to SARS-CoV-2 Coronavirus Respiratory Infection - COVID-19, NCT04355364, clinicaltrials.gov/study/NCT04355364clinicaltrials.gov.

3. Ovalı et al., Determination of Dornase Alpha Effectiveness in COVID-19 Treatment, NCT04432987, clinicaltrials.gov/study/NCT04432987clinicaltrials.gov.

4. Markova et al., A Prospective Open-label Study of the Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19, NCT04459325, clinicaltrials.gov/study/NCT04459325clinicaltrials.gov.

Grégoire et al., 20 Dec 2021, Single Blind Randomized Controlled Trial, France, trial NCT04355364 (history) (COVIDORNASE).

Late treatment
is less effective

Most accessed treatments

Antiviral effects

Vitamins & Minerals

Host endosomal entry / trafficking

Dual-action mAbs

RdRp

Nasal & Oral Sprays / Rinses

Analgesics

Antiandrogens

Host targets and pathways

Inflammatory and immune modulation

Mpro (Gen 1)

Oxidative stress and cytoprotection

Lifestyles

TMPRSS2

Spike neutralization

Replication inhibition (target unresolved)

COVID-19 mAbs

Pleiotropic modulation

Attachment / entry inhibition

Mpro (Gen 2)

H1RAs

Nutrients and microbiome support

Host mAbs

IL-6 / IL-6R blockade

Physical and extracorporeal interventions

Natural products and extracts

Symptom management

Unconfirmed antiviral rationale

Lifestyle, behaviors, and exposure prevention

Other complication management

Mpro / 3CLpro

Host pyrimidine synthesis

Direct viral inactivation

Endothelial / vascular protection

Direct respiratory tract treatments

Other antibodies, proteins, peptides, cells, and RNA therapies

Secondary infection and coinfection management

Efficacy and Safety of Dornase Alfa Aerosol in ARDS Secondary to SARS-CoV-2 Coronavirus Respiratory Infection - COVID-19